i think i have said this before, this lady underestimates the role of shopfloor efforts/commercials by a lot. gormint and industry have been trying to find solutions for a decade. state wanting something alone does not solve things, it has to make financial sense to the companies doing the manufacturing. first PSU bulk drug ecosystem was revived, during covid as it says in the article private players were incentivised with PLI.
it will take a few years for the process to stabilize.
ultimately not just in this sector, every manufacturing sector the economies of scale and FTA are in chini favour, which allows them to produce goods at lower cost. i don't think anyone knows how long this hand holding can continue.
Indian pharma is still very heavily reliant on Chinese API's.
Companies are beginning to make their own API's but the feedback is, API's are cheaper when imported from China.